



C型肝炎ウイルス



プロテアーゼ阻害剤(単剤)の HCV RNA 低下作用 (投与期間: 5 - 14 日間)

プロテアーゼ阻害剤




Note: no head-to-head trials have been conducted to date

*Mean decline; Trt = treatment

1. Lawits E, et al. 59th AASLD 2008;
2. Reesink H, et al. 56th AASLD 2005;
3. Manns M, et al. 59th AASLD 2008;
4. Reesink H, et al. 43rd EASL 2008;
5. Forestier N, et al. 59th AASLD 2008;
6. Zeuzem S, et al. 56th AASLD 2005;

ポリメラーゼ阻害剤(単剤)のHCV RNA低下作用 (投与期間: 8 - 14 日間)



Note: no head-to-head trials have been conducted to date


*Median decline

1. Reddy R, et al. 58th AASLD 2007;
2. Cooper C, et al. 58th AASLD 2007;
3. Hammond J, et al. 59th AASLD 2008;
4. Bavisotto L, et al. 58th AASLD 2007;

Peg-IFN plus Ribavirin plus **STAT-C Drugs:**


Protease inhibitor
Polymerase inhibitor
NS5A inhibitor

Protease inhibitor との併用試験における著効率の比較



(PROVE-1: McHutchison JG, et al. NEJM 2009;360:1827-1838)
 (PROVE-2: Hezode C, et al. NEJM 2009;360:1839-1850)
 (SPRINT-1: Kwo, et al. #4. EASL 2009)

過去の治療歴別著効率 (PROVE 3)



Prior Non-responder


Prior Relapser

(* , p < 0.001; †, p = 0.471, ‡, p = 0.029 compared to P/R48w arm)

In the subgroup of prior viral breakthroughs, SVR rates in the two T/P/R arms were 57% (4/7) and 50% (4/8)

(Manns M et al. #1044. EASL 2009)

TMC435の抗ウイルス効果 (OPERA-1)



TMC435-C205試験の著効率


Treatment	TMC12 PR24	TMC24 PR24	TMC12 PR24	TMC24 PR24	SoC
Dose	75mg q.d.	75mg q.d.	150mg q.d.	150mg q.d.	
Patients	78	75	77	79	77
Week-24	67/73 (92%)	65/67 (92%)	68/74 (92%)	73/78 (94%)	4/18 (22%)
SVR4	59/65 (91%)	56/60 (93%)	57/61 (93%)	63/68 (93%)	NA
SVR12	32/33 (97%)	27/29 (93%)	32/36 (89%)	29/32 (91%)	NA

Genotype-1 naïve patients

MK-7009: 016試験: 本邦における第Ⅱ相試験

試験デザイン

- 対象患者: ジェノタイプ1、既治療患者
- 年齢: 20-64歳
- 主要評価項目: ウイルス陰性化率(4週時)
安全性及び忍容性(6週時)




P: Peg-IFN

R: Ribavirin

<http://clinicaltrials.gov/ct2/show/NCT00880763?term=MK-7009&rank=5>

MK-7009の抗ウイルス効果 (HCV RNA Below < 10 IU/mL)



- HCV RNA kinetics show continued viral suppression even after MK-7009 dosing ended on day 28